Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Software as a Service (SaaS) business for Recruitment generating recurring revenues on a scalable cloud platform. Used by HR, Recruiting Teams and HR Managers. Proven that we can sell to our target market we seek growth capital to build out our chosen go to market strategy.
days to go:
Expired
investment:
£280,000
B-North is a UK-based business lending company. It has combined cloud-native technology with face-to-face relationship banking. The company asserts that SMEs account for over 60% of private-sector employment in the UK, have driven job growth over the past ten years, and are central to driving economic recovery. It intends to disrupt the £150 billion UK Small and Medium Enterprise (SME) lending market. B-North has raised a seed capital of over £6.8 million including a six-figure investment from the Greater Manchester Combined Authority to establish its core team, as well as, build lending and deposit-taking platforms. The company is now seeking further investment through a bridge round to extend the cash runway from the end of Q4 2020 into Q1-Q2 2021 to achieve the necessary regulatory capital to become a bank and commence lending.
days to go:
Expired
investment:
£2,149,256
Byrd is a coaching platform that works around everyday life to keep people running. It asserts that its unique EQAI-coach uses 1 billion variables to coach people to their goal, whether that’s simply to remain healthy or to hit a specific event. The company estimates that 200 million people were running globally in 2018. It seeks to target this group and become a contender in a fitness market that is estimated to be worth $2.4 billion. The company has created and tested two beta versions of its Android and iOS apps. It points out that it has conducted surveys involving hundreds of runners clocking in 20,000 km of running and incorporated that data into its portal. Byrd argues that its app has been built on Google Cloud infrastructure and is ready to horizontally scale. It will use 40% of the investment in product evolution, 20% in acquisition, 23% towards marketing, and 17% towards enriching customer experience.
days to go:
Expired
investment:
£266,836
Appital is an emerging financial market platform that will use digital profiling, unique algorithms and notifications to connect institutional demand and supply. With Appital, corporate and institutional companies within the equity capital markets space will have the opportunity to exchange illiquid equity without an investment bank or broker. Appital will also remove the dependence on email and phone, thereby ensuring efficiency and accessibility. The company is raising fund to built the Appital software, achieve FCA regulation, generate marketing material and gain contracts with partner settlement and KYC providers. Furthermore, the company will enhance the functionality of the software by leveraging its network to other products such as primary debt and primary equity deal flow.
days to go:
Expired
investment:
£349,060
Curiosity Club is a unique curriculum enrichment programme for both primary and secondary schools. Traditionally in schools, all pupils learn the same thing at the same time. Curiosity offers a unique way to engage children by allowing them to choose their own individual journey through the history of time and through that they are developing their skills of literacy, numeracy, research, memory, presentation and communication.
days to go:
Expired
investment:
£42,350
AgeWage is a pension scoring system that provides customized information to the customers. By bringing together your pension pots, AgeWage scores each of the pension pot out of 100 and tells you how well they have worked for you. The scoring system offers information that helps the customer make decisions on how to consolidate pots, reinvest their money and most importantly, how to get their money back. The company has signed an MoU with Royal London to enter into B2B arrangements. It was also chosen for the Direct Support Innovate programme with the FCA. AgeWage has been voted the best new idea in the BGL partnership awards(2018). With its proceeds, the company is planning to invest in digital development, marketing the application to the general public and other organizations. Also, it is trying to build out the infrastructure to support the development of the product with third parties such as Annuity Providers, IFAs, and Drawdown Providers.
days to go:
Expired
investment:
£317,760
